Cargando…
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
Soft-tissue sarcoma (STS) is a heterogeneous group of tumors that arise from mesenchymal tissue. The prognosis of metastatic STS is poor with a life expectancy of 12–18 months. The mainstay of treatment is chemotherapy with an anthracycline. The addition of other chemotherapeutic agents to an anthra...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732568/ https://www.ncbi.nlm.nih.gov/pubmed/29263653 http://dx.doi.org/10.2147/DDDT.S121298 |